Literature DB >> 8165613

The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants.

D A Triplett1, K F Stocker, G A Unger, L K Barna.   

Abstract

Lupus anticoagulants (LA) are immunoglobulins (IgG, IgM, IgA or a mixture) which interfere with in vitro phospholipid (PL) dependent tests of coagulation (e.g. APTT, KCT, dilute Russell Viper Venom Time). LA are heterogeneous; consequently, the laboratory diagnosis is difficult and relies on multiple tests. We have developed a sensitive and relatively specific confirmatory test system based on fractions of two snake venoms. Textarin, a protein fraction of Pseudonaja textilis venom (Australian Eastern brown snake), activates prothrombin in the presence of PL, factor V and calcium ions. Ecarin, a protein fraction of Echis carinatus venom, will activate prothrombin in the absence of any cofactors. The activation of prothrombin by Textarin yields thrombin while Ecarin yields meizothrombin. In the presence of LA, the Textarin time is prolonged and the Ecarin time is unaffected. The test results are reported as a ratio of Textarin/Ecarin times (abnormal greater than 1.3). We have evaluated this test system in the following patient populations: LA positive, therapeutically heparinized, stable oral anticoagulated, liver disease, routine preoperative, anticardiolipin antibody positive LA negative, hemophilia A, various other hereditary factor deficiencies or dysfunctional proteins, and specific inhibitors of factor V and factor VIII. The LA positive patients represented a mixed population of autoimmune disease, drug-induced and post-infectious states. Our findings indicate the sensitivity of the Textarin/Ecarin system in the confirmation of LA. In order to use the test system most effectively, it is recommended to incorporate polybrene with Textarin when evaluating heparinized samples. Factor V deficiency and specific inhibitors of factor V yielded, in some instances, false positive results.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8165613

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies.

Authors:  Wolfgang Miesbach; Inge Scharrer; Ronald Asherson
Journal:  Clin Rheumatol       Date:  2006-01-25       Impact factor: 2.980

2.  Co-existent Acquired Haemophilia and Lupus Anticoagulant. A Thorny Issue.

Authors:  Paul R J Ames; Daniel Montero; Jeremy Archer
Journal:  Indian J Hematol Blood Transfus       Date:  2015-07-22       Impact factor: 0.900

Review 3.  Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.

Authors:  Arne Vandevelde; Katrien M J Devreese
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

4.  Cloning, Expression and Purification of Full-length Recombinant Ecarin and Comparing Its Expression and Function with Its Truncated Form.

Authors:  Zohreh Jafari; Mojgan Bandehpour; Shivasadat Gheflat; Nasrin Mohammadi; Bahram Kazemi
Journal:  Iran J Pharm Res       Date:  2022-01-16       Impact factor: 1.962

Review 5.  Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise.

Authors:  Julien Slagboom; Jeroen Kool; Robert A Harrison; Nicholas R Casewell
Journal:  Br J Haematol       Date:  2017-02-24       Impact factor: 6.998

6.  Toxinology provides multidirectional and multidimensional opportunities: A personal perspective.

Authors:  R Manjunatha Kini
Journal:  Toxicon X       Date:  2020-05-11

7.  Antiphospholipid Antibodies in Sickle Cell Disease: A Systematic Review and Exploratory Meta-Analysis.

Authors:  Mira Merashli; Alessia Arcaro; Maria Graf; Matilde Caruso; Paul R J Ames; Fabrizio Gentile
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

8.  Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation.

Authors:  W Miesbach; I Scharrer; R A Asherson
Journal:  Clin Rheumatol       Date:  2004-03-20       Impact factor: 2.980

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.